- Written by GlobalData's senior healthcare analyst for infectious diseases, Dr. Ramya Kartikeyan.
On July 30th, Vertex Pharmaceuticals released a statement highlighting positive results from their initial Phase I trials testing the hepatitis C virus (HCV) therapy, ALS-2200. HCV currently infects about 3% of the world’s population, and as many as eleven genotypic strains have been identified worldwide. Genotype 1 HCV has been implicated in most chronic HCV infections and poses a significant healthcare concern. ALS-2200, a nucleotide analogue therapy, was administered to eight individuals suffering from chronic viral infection by HCV genotype 1, and all patients registered significant decreases in viral RNA after treatment. Patients were provided a daily dose of 220mg of ALS-2200 over a period of a week. The study also showed that viral loads were decreased as early as three days after dosing and effects were sustained for two days after the completion of the regimen.
Registering for our Expert Insights is free and only takes a moment.
Following this you'll gain unlimited access to all of the latest, event-driven opinion put together by our teams of experienced analysts.